Eculizumab (Soliris) for prevention of delayed graft function after kidney transplantation in adult patients at increased risk – first line
NIHR HSRIC
Record ID 32016001036
English
Authors' recommendations:
Eculizumab is a drug to prevent delayed graft function in people who have undergone a kidney transplant and are at a high risk of this complication. Delayed graft function means the transplant is not working effectively enough and that dialysis is needed within a week of transplantation. Eculizumab is delivered straight into the blood and prevents an immune response which may be the cause of delayed graft function.
Details
Project Status:
Completed
Year Published:
2016
URL for published report:
http://www.hsric.nihr.ac.uk/topics/eculizumab-soliris-for-prevention-of-delayed-graft-function-after-kidney-transplantation-in-adult-patients-at-increased-risk-first-line/
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
England, United Kingdom
MeSH Terms
- Humans
- Adult
- Antibodies, Monoclonal, Humanized
- Atypical Hemolytic Uremic Syndrome
- Delayed Graft Function
- Kidney Transplantation
- Risk
Contact
Organisation Name:
NIHR Horizon Scanning Centre
Contact Address:
The NIHR Horizon Scanning Centre, Department of Public Health, Epidemiology, and Biostatistics, School of Health and Population Sciences, University of Birmingham, 90 Vincent Drive, Edgbaston, Birmingham, B15 2SP. United Kingdom. Tel: +44 121 414 7831, Fax: +44 121 2269
Contact Name:
c.packer@bham.ac.uk
Contact Email:
c.packer@bham.ac.uk
Copyright:
NIHR Horizon Scanning Research&Intelligence Centre (NIHR HSRIC)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.